A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension
Part of paid clinical trials in Norfolk, Virginia.
- Sponsor
- Cosmos Rx, Inc
- Study ID
- NCT07613216
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Pulmonary Hypertension
- Sarcoidosis Lung
- Usual Interstitial Pneumonia
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks prescription bottle openings and sends dose reminders to participants and their care team - take their medications more consistently and experience better health outcomes compared to similar participants receiving standard care without the device. Participation requires no changes to prescribed medications, testing or clinical visits beyond what is already part of routine care; participants use a modified medication bottle equipped with the FORTISKAP™ cap for nine months.
Key Dates
- Start date
- Jul 31, 2026
- Status verified
- May 2026
- Primary completion
- Jul 31, 2027
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 100 participants (estimated)
Arms
- Arm: Fortiskap GroupProspective Cohort equipped with medication adherence monitoring device
- Arm: Historical ControlsHistorical Control group (retrospective cohort)
Primary Outcome Measure
6 minute walk test [ Time Frame: 9 months ]
Central Contacts
- Abraham N Morse, MD,MBA5082437396
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Pulmonary Disease Clinic, Sentara Norfolk Hospital | Norfolk | Virginia | 23507 | Matthew Bernens, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Norfolk, VA
Related Studies
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPHASE3 · Enrolling By Invitation · United Therapeutics · Phoenix, Arizona
- Pulmonary Hypertension Association RegistryRecruiting · Pulmonary Hypertension Association, Inc. · Phoenix, Arizona
- LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFPHASE3 · Recruiting · Tenax Therapeutics, Inc. · Tucson, Arizona
- DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Recruiting · United Therapeutics · Birmingham, Alabama